accord
recent
statist
million
appar
dengu
infect
estim
worldwid
figur
far
greater
predict
indic
rapid
spread
diseas
pose
grow
threat
economi
major
challeng
clinician
health
care
servic
across
globe
particularli
affect
area
articl
aim
bring
light
current
epidemiolog
clinic
statu
dengu
fever
relationship
genet
mutat
singl
nucleotid
polymorph
snp
pathophysiolog
diseas
progress
put
perspect
also
highlight
recent
advanc
dengu
vaccin
develop
thu
far
signific
progress
made
unravel
risk
factor
understand
molecular
pathogenesi
associ
diseas
howev
insight
molecular
featur
diseas
develop
anim
model
enorm
help
improv
therapeut
intervent
potenti
contribut
find
new
prevent
measur
popul
risk
dengu
fever
major
caus
ill
death
worldwid
diseas
caus
dengu
viru
get
transmit
human
bite
infect
mosquito
aed
ae
aegypti
ae
albopictu
diseas
repres
global
health
issu
endem
around
countri
tropic
subtrop
area
last
decad
incid
rate
geograph
distribut
dengu
rapidli
increas
almost
data
world
health
organ
estim
million
case
dengu
fever
year
howev
recent
publish
work
bhatt
et
al
suggest
burden
dengu
far
estim
indic
million
infect
dengu
viru
could
happen
everi
year
chang
dengu
epidemiolog
increas
incid
rate
without
comorbid
led
propos
new
dengu
classif
system
accord
diseas
sever
fig
dengu
fever
caus
infect
dengu
viru
denv
denv
vectorborn
viru
transmit
human
primarili
bite
two
mosquito
speci
ae
aegypti
ae
albopictu
denv
singl
positivestrand
rna
viru
belong
flaviviru
genu
flavivirida
famili
major
serotyp
denv
antigen
distinct
denv
serotyp
phylogenet
distinct
suggest
serotyp
could
consid
separ
viru
three
dengu
serotyp
four
denv
found
middl
eastern
countri
includ
saudi
arabia
yemen
interestingli
strain
isol
saudi
arabia
exhibit
high
genet
similar
strain
isol
asian
popul
suggest
widespread
asian
genotyp
probabl
asian
pilgrim
recent
publish
articl
unveil
new
serotyp
ad
exist
one
discoveri
still
controversi
littleknown
enough
conclud
th
dengu
serotyp
might
add
burden
associ
dengu
infect
mosquito
transmit
viru
feed
blood
infect
person
first
viru
infect
replic
midgut
epithelium
mosquito
spread
organ
reach
salivari
gland
day
inocul
anoth
person
subsequ
blood
meal
vertic
transmiss
denv
mosquito
ie
mosquito
larva
report
number
research
group
india
angel
joshi
report
detect
dengu
viru
indirect
fluoresc
antibodi
test
ifat
laboratori
rear
mosquito
origin
larva
collect
urban
rural
area
similar
studi
conduct
brazil
martin
et
al
confirm
isol
denvtyp
ae
albopictu
larva
denvtyp
ae
aegypti
larva
similar
find
also
report
mexico
indonesia
hand
mothertoinf
transmiss
dengu
viru
via
cord
blood
breast
milk
remain
controversi
base
result
sever
studi
launch
new
dengu
classif
classif
divid
dengu
case
case
withwithout
warn
sign
b
sever
dengu
case
howev
import
note
numer
research
group
debat
ration
classif
fit
uniqu
local
set
criteria
dengu
case
classif
present
fig
clinic
dengu
infect
broad
spectrum
featur
vast
major
case
asymptomat
pass
unnot
typic
symptom
start
promin
incub
period
day
sever
clinic
manifest
vari
mild
symptom
sever
life
threaten
symptom
case
dengu
hemorrhag
fever
dhf
dengu
shock
syndrom
dss
predict
progress
mild
sign
sever
dhfdss
remain
challeng
due
nonspecif
clinic
present
incomplet
understand
pathophysiolog
diseas
underli
molecular
mechan
earli
sign
diseas
nonspecif
accord
classif
df
character
febril
episod
day
frequent
associ
rash
nausea
vomit
headach
although
diseas
affect
peopl
age
infanc
adulthood
epidemiolog
data
show
children
tend
toler
phase
ill
better
adult
persist
aforement
symptom
appear
symptom
abdomin
pain
mucos
bleed
lethargi
restless
seen
day
later
laboratori
analysi
mild
dengu
fever
case
usual
show
abnorm
leukocyt
count
moder
elev
hepat
aminotransferas
enzym
activ
emerg
symptom
warn
sign
diseas
progress
sever
form
dhfdss
therapeut
intervent
undertaken
stage
clinic
intervent
continu
surveil
imper
prevent
vascular
leakag
especi
endem
area
form
dengu
infect
attribut
four
known
serotyp
denv
likelihood
develop
dhfdss
high
patient
experienc
dengu
infect
past
heterogen
serotyp
patient
progress
develop
sever
dhfdss
fatal
unless
treat
promptli
form
develop
late
stage
df
patient
may
go
defervesc
phase
character
sudden
drop
bodi
temperatur
phase
also
distinguish
sever
bleed
particularli
bleed
gastrointestin
tract
black
tarri
stool
thrombocytopenia
may
affect
dhf
case
interestingli
observ
neg
correl
sever
dhf
level
platelet
blood
exact
mechan
correl
yet
delin
drop
platelet
count
loss
function
lead
vascular
fragil
increas
risk
hemorrhag
plasma
leakag
suggest
acut
phase
infect
denv
replic
quickli
platelet
critic
viru
surviv
dissemin
exist
symptom
retroorbit
pain
maculopapular
rash
petechia
bleed
nose
gum
help
make
definit
diagnosi
df
evid
plasma
leakag
variou
bodi
caviti
pleural
caviti
periton
caviti
associ
profus
perspir
adynamia
sometim
faint
sign
rapid
progress
shock
subsid
systol
pressur
hypotens
may
result
profound
shock
known
dengu
shock
syndrom
dss
durat
dss
long
time
might
predispos
complic
massiv
bleed
dissemin
intravascular
coagulopathi
dic
respiratori
failur
multiorgan
failur
infrequ
encephalopathi
lead
death
propos
case
fatal
relat
dhf
may
reach
case
howev
proper
medic
care
symptomat
manag
reduc
mortal
rate
less
earli
accur
laboratori
diagnosi
dengu
infect
paramount
import
manag
diseas
estim
number
misdiagnos
dengu
case
could
reach
record
ratio
case
mainli
due
larg
dispar
dengu
sign
symptom
overlap
symptom
viral
infect
especi
person
live
travel
endem
area
tropic
infecti
diseas
dengu
fever
distinguish
ill
share
similar
symptom
chikungunya
mayaro
fever
ross
river
fever
west
nile
fever
zika
fever
yellow
fever
viral
hemorrhag
fever
antivir
vaccin
becom
avail
prevent
sever
case
cutdown
econom
burden
diseas
reli
enorm
earli
accur
diagnosi
latter
made
possibl
avail
sever
diagnost
laboratori
virolog
test
onset
later
stage
symptom
ill
overwhelm
pathognomon
nonetheless
base
classif
scheme
appear
leukopenia
patient
febril
ill
major
consider
make
diagnosi
dengu
infect
overal
urgent
need
reduc
dengu
morbid
mortal
improv
diagnosi
molecular
analysi
emerg
dengu
viru
thu
far
two
diagnost
modal
appli
detect
diseas
earli
stage
first
one
direct
method
target
acut
phase
dengu
diseas
base
upon
detect
genom
rna
rtqpcr
solubl
antigen
captur
blood
sampl
virem
patient
second
indirect
method
reli
serolog
test
detect
denguerel
immunoglobulin
par
macelisa
captur
specif
igm
indirect
elisa
captur
antiden
igg
sever
risk
factor
associ
dengu
infect
progress
sever
dhfdss
form
recent
advanc
molecular
biolog
reveal
genet
makeup
three
element
dengu
infect
viru
vector
host
play
primordi
role
pathogenesi
diseas
could
potenti
contribut
dhf
progress
henc
indepth
analysi
genet
variabl
includ
polymorph
mutat
could
benefici
identifi
possibl
factor
mechan
diseas
develop
list
host
genet
factor
confer
suscept
resist
dengu
infect
summar
tabl
like
arbovirus
denv
infect
differ
organ
mosquito
includ
salivari
gland
central
nervou
system
mosquito
infect
elicit
behavior
chang
includ
increas
probe
time
lead
host
interrupt
might
lead
wider
spread
viru
demonstr
denv
infect
induc
express
cathepsinb
put
cystatin
hypothet
ankyrin
repeatcontain
protein
gene
latter
could
alter
effici
viru
replic
salivari
gland
studi
shown
modul
gene
express
well
denv
infectionrespons
odorantbind
protein
gene
increas
time
length
initi
probe
success
blood
meal
result
chang
host
seek
behavior
mosquito
compar
analysi
salivari
gland
transcriptom
nativ
denvinfect
ae
aegypti
identifi
number
differenti
express
gene
relat
sugarprotein
digest
enzym
immun
relat
gene
blood
meal
acquisit
enzym
might
impact
effici
viral
replic
mosquito
feed
behavior
studi
show
denv
infect
alter
express
key
hostseek
gene
mosquito
main
olfactori
organ
antenna
recent
updat
indic
resist
ae
aegypti
convent
insecticid
relat
differ
mechan
one
associ
genet
abnorm
within
vector
genom
singl
point
mutat
voltageg
sodium
channel
gene
posit
result
phenylalanin
cystein
substitut
ae
aegypti
confer
resist
permethrin
mutat
widespread
vector
southeast
asia
latin
america
also
report
singl
amino
acid
substitut
valin
glycin
posit
domain
ii
segment
voltageg
sodium
channel
gene
associ
less
sensibl
ae
aegypti
deltamethrin
thailand
numer
multidisciplinari
studi
confirm
race
young
age
viru
strain
femal
sex
high
bodymass
index
correl
well
increas
burden
dengu
thu
closer
consider
human
gene
regul
sever
dengu
infect
especi
gene
associ
immun
respons
might
help
control
diseas
spread
improv
acut
symptom
infect
number
studi
investig
relationship
host
genet
polymorph
denv
infect
tabl
singl
nucleotid
polymorph
snp
promot
associ
increas
risk
develop
dengu
fever
associ
studi
success
identifi
link
polymorph
human
majorhistocompatibilitycomplex
hla
class
iii
gene
nonhla
host
genet
factor
sever
dengu
diseas
polymorph
gene
could
directli
associ
risk
develop
dengu
diseas
among
primaryinfect
individu
locat
within
mhc
class
ii
region
homozygos
posit
posit
respect
found
protect
develop
sever
form
dengu
independ
studi
author
show
singl
nucleotid
polymorph
oligoadenyl
synthetas
gene
oasrnas
l
antivir
immun
system
enhanc
suscept
clinic
outcom
dengu
infect
associ
sever
diseas
gene
includ
human
leukocyt
antigen
class
class
ii
gene
tumor
necrosi
factoralpha
fcgriia
vitamin
receptor
transport
associ
antigen
present
also
propos
import
vitd
denv
pathogenesi
conclud
newlygath
data
show
vitd
impair
denv
replic
polymorph
vitd
gene
increas
express
fcgriia
receptor
enhanc
denv
entri
target
cell
anoth
studi
author
success
appli
genomewid
associ
studi
gwa
approach
identifi
loci
confer
suscept
sever
form
dengu
diseas
investig
use
sampl
children
affect
sever
dengu
infect
popul
control
case
vietnam
data
show
snp
two
loci
micb
significantli
increas
likelihood
develop
dss
children
find
valid
independ
cohort
case
control
snp
micb
gene
code
mhc
class
polypeptiderel
sequenc
b
induc
activ
ligand
type
ii
receptor
immun
cell
could
alter
protect
role
natur
killer
cell
host
respons
denv
earli
stage
infect
hand
play
primordi
role
maintain
intact
vascular
endotheli
cell
barrier
function
henc
polymorph
gene
may
lead
blood
vessel
leakag
circulatori
hypovolemia
dss
host
candid
gene
also
associ
earli
onset
dengu
diseas
among
gene
receptorsattach
factor
denv
link
immun
system
inflammatori
respons
chemokin
respect
chemokin
receptor
report
biomark
sever
form
dengu
infect
result
agreement
recent
emerg
data
indic
strong
associ
vascular
permeabl
three
gene
compon
nfkb
pathway
involv
pathogenesi
sar
west
nile
viru
enceph
process
depend
enorm
vectorderiv
salivari
factor
inocul
skin
cell
tilldat
effect
commerci
avail
therapyvaccin
dengu
viru
numer
group
alreadi
made
intens
effort
made
good
progress
develop
safe
afford
effect
vaccin
serotyp
global
public
health
vaccin
develop
use
variou
approach
live
attenu
virus
inactiv
virus
subunit
vaccin
dna
vaccin
chimer
virus
use
yellow
fever
vaccin
attenu
dengu
virus
backbon
tabl
current
one
tetraval
vaccin
dengu
viru
develop
sanofipasteur
franc
reach
phase
iii
clinic
trial
expect
launch
vaccin
base
product
four
chimer
live
dengueyellow
fever
virus
yellow
fever
yf
vaccin
sequenc
encod
envelop
protein
prm
e
gene
substitut
prm
e
gene
dv
serotyp
molecular
clone
vaccin
produc
test
peopl
use
four
dengu
viru
isol
indonesia
thailand
candid
vaccin
found
attenu
stabl
anim
model
respect
plaqu
size
yellow
fever
viru
neurotrop
result
clinic
trial
show
advers
effect
except
moder
inject
site
pain
headach
myalgia
anoth
random
control
trial
launch
use
total
thai
school
children
investig
efficaci
recombin
tetraval
vaccin
dengu
viru
dengu
case
report
phase
trial
vaccin
philippin
show
seroposit
increas
gradual
vaccin
four
serotyp
compar
control
group
promis
result
observ
children
year
old
exhibit
high
level
reactiv
denv
respect
anoth
placebocontrol
trial
conduct
children
vietnam
vaccin
n
vs
placebo
n
determin
clinic
efficaci
safeti
cydtdv
result
demonstr
virologicallyconfirm
case
vaccin
group
compar
control
group
efficaci
achiev
ci
find
indic
vaccin
highli
efficaci
good
safeti
profil
three
inject
given
children
age
group
year
month
interv
data
emerg
anoth
random
phase
ii
trial
india
indic
vaccin
seriou
advers
event
immunogen
safeti
cydtdv
satisfactori
pilot
studi
carri
five
latin
american
countri
children
age
recruit
receiv
either
cydtdv
vaccin
placebo
result
efficaci
safeti
profil
consist
previou
find
interestingli
vaccin
efficaci
hospit
dengu
promis
repres
step
forward
develop
effect
dengu
vaccin
candid
dengu
vaccin
develop
usa
john
hopkin
univers
nation
institut
allergi
infecti
diseas
niaid
reach
advanc
clinic
trial
four
liveattenu
gener
contain
nucleotid
delet
region
genom
rna
vaccin
effici
impair
viral
growth
human
liver
carcinoma
cell
improv
attenu
chimer
denv
develop
substitut
prme
gene
region
viru
prme
gene
result
phase
clinic
trial
show
four
liveattenu
denv
safe
immunogen
minor
side
effect
faint
rash
transient
leucopenia
higher
dose
dengu
viru
antigen
express
vector
base
pediatr
liveattenu
schwarz
measl
vaccin
mv
use
envelop
domain
iii
ediii
fuse
ectodomain
membran
protein
ectom
immun
longterm
product
serotypespecif
neutral
antibodi
observ
measl
viru
suscept
mice
new
strategi
evalu
base
singl
minim
tetraval
denv
antigen
express
use
viral
vector
deriv
pediatr
liveattenu
measl
vaccin
mv
recombin
mv
vaccin
construct
develop
use
envelop
domain
iii
ediii
ectodomain
membran
protein
neutral
antibodi
induc
four
serotyp
dengu
viru
two
inject
mice
suscept
mv
infect
strong
memori
neutral
respons
observ
four
serotyp
immun
mice
inocul
live
denv
serotyp
nake
dnabas
candid
vaccin
denv
develop
naval
medic
research
center
gene
encod
prm
e
denv
clone
shuttl
vector
transcript
control
human
cytomegaloviru
cmv
promot
result
phase
clinic
trial
show
advers
effect
except
mild
inject
site
pain
swell
fatigu
second
dose
strong
igm
igg
antibodi
respons
observ
favor
safeti
profil
vaccin
get
better
immunogen
profil
vaccin
base
lipid
adjuv
vaxfectin
vical
incorpor
san
diego
usa
develop
result
demonstr
good
protect
profil
denv
compar
dna
alon
base
technolog
differ
group
develop
candid
vaccin
achiev
good
protect
mous
model
use
envelop
glycoprotein
prm
e
nonstructur
protein
helicaseproteas
vaccin
antigen
first
purifi
inactiv
vaccin
develop
aluminum
hydroxid
alum
adjuv
test
mice
rhesu
macaqu
walter
reed
armi
institut
research
dengu
serotyp
good
viru
protect
report
two
dose
use
similar
technolog
second
gener
japanes
enceph
je
piv
vaccin
develop
current
new
je
vaccin
ixiaro
novarti
vaccin
approv
use
mani
countri
includ
usa
anoth
dengu
vaccin
dengu
piv
recombin
subunit
dengu
e
glycoprotein
antigen
also
develop
enter
phase
clinic
trial
center
diseas
control
prevent
usa
also
develop
liveattenu
vaccin
name
denvax
found
highli
immunogen
children
adult
current
enter
phase
clinic
trial
unit
state
recent
novel
third
gener
approach
use
develop
vaccin
contain
recombin
subunit
e
domain
iii
result
laboratori
test
shown
develop
potent
neutral
antibodi
mous
model
use
technolog
tetraval
vaccin
develop
express
pichia
pastori
splice
use
flexibl
pentaglycyl
linker
four
ediii
observ
result
show
antigen
elicit
specif
antibodi
four
denv
serotyp
balbc
mice
anim
model
use
vaccin
test
develop
lack
anim
model
significantli
hamper
develop
efficaci
test
dengu
vaccin
current
rhesu
macaqu
aotu
monkey
use
test
vaccin
clinic
trial
initi
vaccin
evalu
aotu
monkey
rhesu
monkey
found
immunogen
protect
dengu
infect
porter
et
al
demonstr
inject
nonhuman
primat
three
dose
day
tetraval
dengu
dna
vaccin
vaxfectinadjuv
effici
live
viru
compar
control
anim
find
support
initi
vaxfectinadjuv
phase
clinic
trial
success
induct
immun
respons
obtain
mice
rhesu
monkey
vaccin
develop
use
dengu
prme
dengu
prmenonstructur
ns
dengu
antigen
piv
adjuv
alum
center
diseas
control
prevent
fort
collin
co
hawaii
biotech
simmon
develop
differ
vaccin
show
good
immunogen
anim
model
similarli
psoralenuv
inactiv
dengu
vaccin
found
immunogen
protect
dengu
serotyp
viru
aotu
monkey
thu
far
antivir
drug
avail
treat
dengu
fever
therefor
commun
continu
depend
control
mosquito
vector
main
rout
prevent
spread
diseas
altern
approach
util
flavivirus
target
inhibit
viru
entri
essenti
element
use
viru
replic
nonstructur
protein
rna
polymeras
proteas
import
target
element
includ
helicas
nucleosid
triphosphatas
ntpase
rna
triphosphatas
rtpase
methyl
transferas
rnadepend
rna
polymeras
proteas
rna
interfer
rnai
technolog
also
use
impair
viru
replic
respiratori
syncyti
viru
hepat
virus
influenza
viru
polioviru
hiv
low
molecular
weight
phenol
compound
flavonoid
phytochem
isol
plant
previous
test
use
antidengu
therapi
antivir
inhibitori
effect
rang
denv
replic
observ
methanol
extract
momordica
charantia
andrographi
paniculata
use
cultur
primat
cell
sever
attempt
made
past
tackl
dengu
elimin
ae
aegypti
success
experi
relat
vector
control
program
adopt
cuba
singapor
program
base
intens
insecticid
treatment
reduct
avail
aed
larval
habitat
unfortun
lack
sustain
stringent
measur
led
reappear
dengu
outbreak
recent
novel
form
biolog
control
dengu
transmiss
develop
current
appli
base
develop
genet
modifi
gm
mosquito
infect
bacterium
known
wolbachia
combat
dengu
infect
bacterium
block
replic
viru
insid
mosquito
prevent
transmiss
human
million
gm
male
mosquito
releas
wild
decreas
number
aed
mosquito
reduc
rate
dengu
transmiss
closer
monitor
insect
reveal
egg
wolbachiaposit
indic
gmmosquito
overrid
wildmosquito
result
decreas
viru
transmiss
initi
erad
dengu
fever
scientist
australia
lead
elimin
dengu
ed
program
involv
commun
engag
key
compon
program
sinc
program
kick
million
wolbachia
mosquito
releas
across
north
queensland
cityaustralia
base
promis
result
obtain
local
trial
elimin
dengu
becam
intern
research
program
across
countri
affect
dengu
includ
australia
vietnam
indonesia
brazil
colombia
dengu
infect
prevent
altern
approach
first
one
includ
block
viru
entri
cell
mediat
viral
envelop
glycoprotein
e
via
receptormedi
endocytosi
dendrit
cell
monocyt
macrophag
main
target
denv
infecti
entri
second
approach
involv
block
viru
attach
specif
cellular
receptor
express
immun
cell
liver
cell
endotheli
cell
small
molecul
peptid
target
hydrophob
pocket
envelop
e
glycoprotein
character
inhibitor
viru
entri
nicholson
et
al
explor
inhibitori
effect
peptid
entri
inhibitor
author
demonstr
effect
block
antibodi
depend
enhanc
ade
invitro
suggest
entri
inhibitor
potenti
candid
prevent
develop
dhf
dss
two
compound
also
shown
qualifi
potent
inhibitor
dengu
viru
infect
iminosugar
deoxynojirimycin
castanospermin
compound
natur
alkaloid
deriv
black
bean
act
inhibitor
dengu
serotyp
disrupt
fold
pathway
envelop
glycoprotein
prm
e
variou
type
carbohydratebind
agent
isol
differ
organ
shown
antivir
activ
three
plant
lectin
hippeastrum
hybrid
agglutinin
galanthu
nivali
agglutinin
urtica
dioica
agglutinin
isol
amarylli
snowdrop
sting
nettl
respect
found
potent
inhibitor
infect
inhibit
viral
replic
heparan
sulfat
hs
put
receptor
denv
interact
domain
iii
eprotein
viru
entri
block
target
eproteinh
interact
solubl
gag
highli
charg
hs
fucoidan
isol
marin
alga
show
antivir
activ
bhk
cell
similarli
carrageenan
dl
galactan
sulfat
polysaccharid
red
seawe
exhibit
strong
antivir
activ
weak
activ
furthermor
two
isol
chines
herb
demonstr
high
activ
bhk
cell
dengu
fever
repres
real
econom
burden
especi
affect
countri
extens
effort
need
tackl
diseas
spread
reduc
mortal
rate
associ
healthcar
cost
need
scientif
research
believ
key
rout
provid
insight
pathogenesi
dengu
infect
help
understand
underli
molecular
mechan
associ
progress
sever
form
diseas
dhfdss
step
forward
develop
adequ
prevent
vaccin
effect
treatment
author
disclos
conflict
interest
author
contribut
tn
particip
review
design
coordin
help
draft
manuscript
sk
ss
particip
review
design
help
draft
manuscript
pd
particip
articl
revis
gd
ea
particip
review
design
read
approv
final
manuscript
project
fund
king
abdulaziz
citi
scienc
technolog
kacst
grant
number
author
also
grate
